Hengzi Sun1, Xiang Wang2, Yifang Zhang3, Xiaoxia Che1, Zhiming Liu1, Lili Zhang4, Chunping Qiu1, Qingtao Lv5, Jie Jiang6. 1. Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 107 Wenhuaxi Road, Jinan, 250012, Shandong, China. 2. Jinan Maternity and Child Care Hospital, Jinan, Shandong, China. 3. Department of Obstetrics and Gynecology, Affiliated Hospital of Taishan Medical University, Taian, Shandong, China. 4. Jinan Central Hospital Affiliated to Shandong University, Jinan, China. 5. Department of Traditional Chinese Medicine, Shandong University, Jinan, China. 6. Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 107 Wenhuaxi Road, Jinan, 250012, Shandong, China. qljiangjie@sdu.edu.cn.
Abstract
OBJECTIVE: This study aimed to confirm that biglycan (BGN) can promote the migration and invasion in endometrial cancer both in vitro and in vivo and the possible therapeutic value of BGN in endometrial cancer. METHODS: Western blot was used to screen out the higher protein level of BGN in human endometrial cancer cells; BGN knocked down cells were constructed by lentiviral transfection; The effect of BGN in endometrial cancer detected by wound healing, transwell migration, and invasion, endothelial tube formation assay in vitro, and xenograft model in vivo. RESULTS: (1) We found that BGN expression level is higher in the Ishikawa (ISK, high differentiation) and AN3CA (poor differentiation) cells than other endometrial cancer cells. (2) BGN enhances endometrial cancer cell wound healing, invasion, and migration ability and formation ability of endothelial cells in vitro. Xenograft model has confirmed the outcome in vivo. CONCLUSIONS: BGN might play an important role on metastasis in human endometrial cancer and it might be a target marker for the molecular therapy of advanced and recurrence endometrial cancer.
OBJECTIVE: This study aimed to confirm that biglycan (BGN) can promote the migration and invasion in endometrial cancer both in vitro and in vivo and the possible therapeutic value of BGN in endometrial cancer. METHODS: Western blot was used to screen out the higher protein level of BGN in humanendometrial cancer cells; BGN knocked down cells were constructed by lentiviral transfection; The effect of BGN in endometrial cancer detected by wound healing, transwell migration, and invasion, endothelial tube formation assay in vitro, and xenograft model in vivo. RESULTS: (1) We found that BGN expression level is higher in the Ishikawa (ISK, high differentiation) and AN3CA (poor differentiation) cells than other endometrial cancer cells. (2) BGN enhances endometrial cancer cell wound healing, invasion, and migration ability and formation ability of endothelial cells in vitro. Xenograft model has confirmed the outcome in vivo. CONCLUSIONS:BGN might play an important role on metastasis in humanendometrial cancer and it might be a target marker for the molecular therapy of advanced and recurrence endometrial cancer.
Authors: Pia Boström; Annele Sainio; Natalja Eigėlienė; Anne Jokilammi; Klaus Elenius; Ilkka Koskivuo; Hannu Järveläinen Journal: Cancer Microenviron Date: 2017-06-26
Authors: Frank Jacobsen; Juliane Kraft; Cornelia Schroeder; Claudia Hube-Magg; Martina Kluth; Dagmar S Lang; Ronald Simon; Guido Sauter; Jakob R Izbicki; Till S Clauditz; Andreas M Luebke; Andrea Hinsch; Waldemar Wilczak; Corinna Wittmer; Franziska Büscheck; Doris Höflmayer; Sarah Minner; Maria Christina Tsourlakis; Hartwig Huland; Markus Graefen; Lars Budäus; Imke Thederan; Georg Salomon; Thorsten Schlomm; Nathaniel Melling Journal: Neoplasia Date: 2017-08-19 Impact factor: 5.715